Base Therapeutics (Shanghai) Co., Ltd.

Floor 1, Building F, 200 Jinsu Rd, Pudong New District, Shanghai, China

Clinical Trials

4 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Early Phase 1

44.4%

Phase 1

44.4%

Not Applicable

11.1%

Trial Status Distribution

Enrolling By Invitation

11.1%

Not yet recruiting

33.3%

Recruiting

55.6%

Clinical Trials

Trials sponsored by this organization (9)

NK521 in the Treatment of Advanced Solid Tumors

Phase 1

Not yet recruiting

interventional

Jun 202618 participants

NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors

Phase 1

Recruiting

interventional

Mar 202618 participants

Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer

Phase 1

Not yet recruiting

interventional

Nov 202515 participants

NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus

Not Applicable

Not yet recruiting

interventional

Aug 20259 participants

Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

Early Phase 1

Recruiting

interventional

Jul 20249 participants

Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

Early Phase 1

Recruiting

interventional

Jul 20249 participants

Safety and Efficacy of NK510 to Treat Gastric Cancer

Early Phase 1

Enrolling By Invitation

interventional

Nov 20239 participants

Safety and Efficacy of NK510 to Treat NSCLC

Phase 1

Recruiting

interventional

Jul 202312 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations